This compound, when tested on RCC cell lines A498 and ACHN, proved to be effective in upregulating pro-apoptotic proteins, such as p53, Bax, p21, and the active forms of caspase-3 and caspase-7 (diminishing their pro-active forms), and in downregulating the anti-apoptotic Bcl-2 and Bcl-xL. The gene discussed is TP53; the disease is renal cell adenocarcinoma.